28 Feb New Ninevalent HPV Vaccine Gives Greater Protection Against Cervical Cancer and Genital Warts

MedicalResearch.com Interview with:
Elmar A. Joura, M.D
Gynecologist
University of Vienna

MedicalResearch: What are the main findings of this study?

Dr. Joura: This study demonstrates that the new ninevalent HPV vaccine induces a good immunogenicity against HPV 6/11/16/18 and gives a 97% protection against disease caused by HPV 31/33/45/52/58. This has a potential of a 90% reduction of cervical cancer and other HPV related cancers and a similar protection against genital warts. The full benefit is seen in persons without current HPV infection, this reinforces early vaccination against HPV. The safety profile was favourable.

MedicalResearch: What future research do you have planned as a result of this work?

Dr. Joura: Long term follow up studies have been initiated.

Citation:

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

Elmar A. Joura, M.D., Anna R. Giuliano, Ph.D., Ole-Erik Iversen, M.D., Celine Bouchard, M.D., Constance Mao, M.D., Jesper Mehlsen, M.D., Edson D. Moreira, Jr., M.D., Yuen Ngan, M.D., Lone Kjeld Petersen, M.D., Eduardo Lazcano-Ponce, M.D., Punnee Pitisuttithum, M.D., Jaime Alberto Restrepo, M.D., Gavin Stuart, M.D., Linn Woelber, M.D., Yuh Cheng Yang, M.D., Jack Cuzick, Ph.D., Suzanne M. Garland, M.D., Warner Huh, M.D., Susanne K. Kjaer, M.D., Oliver M. Bautista, Ph.D., Ivan S.F. Chan, Ph.D., Joshua Chen, Ph.D., Richard Gesser, M.D., Erin Moeller, M.P.H., Michael Ritter, B.A., Scott Vuocolo, Ph.D., and Alain Luxembourg, M.D., Ph.D. for the Broad Spectrum HPV Vaccine Study

N Engl J Med 2015; 372:711-723
February 19, 2015
DOI: 10.1056/NEJMoa1405044

[wysija_form id=”2″]

MedicalResearch.com Interview with:, & Elmar A. Joura, M.D (2015). New Ninevalent HPV Vaccine Gives Greater Protection Against Cervical Cancer and Genital Warts MedicalResearch.com

Last Updated on March 1, 2015 by Marie Benz MD FAAD